Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our meta-analysis suggested that the XPC Lys939Gln polymorphism contributed to the risk of urinary bladder cancer.
|
23819639 |
2013 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study has genotyped 334 subjects from North Indian population for xeroderma pigmentosum complementation Group C (XPC) rs2228001A>C, XPC rs77907221 polyadenylate (PAT) deletion/insertion (D/I), xeroderma pigmentosum complementation Group D - rs13181A>C, and xeroderma pigmentosum complementation Type G rs17655 G>C polymorphisms with polymerase chain reaction (PCR)-restriction-fragment length polymorphism or allele-specific PCR methods.
|
29893334 |
2018 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the second part we selected 2 common single nucleotide polymorphisms within genes involved in NER (Xeroderma pigmentosum group C (XPC) Lys939Gln, Xeroderma pigmentosum group D (XPD) Lys751Gln) to determine the relation between them and CRC risk.
|
29793654 |
2018 |
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this work, we have conducted a case-control study in order to assess the effect of tobacco and three genetic polymorphisms in XPC, ERCC2 and ERCC5 genes (rs2228001, rs13181 and rs17655) in bladder cancer development in Tunisia.
|
21426550 |
2011 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Three SNPs showed a main association with advanced prostate cancer risk after multiple testing correction: catalase (CAT) rs511895, prostaglandin-endoperoxide synthase 2 (PTGS2) rs5275, and xeroderma pigmentosum group C (XPC) rs2228001.
|
29697282 |
2019 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
To quantitatively elucidate the genetic impact of the <i>XPC</i> rs2228000 and rs2228001 polymorphisms on the response to platinum-based chemotherapy, the present meta-analysis was conducted.
|
31190883 |
2019 |
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Meta-analyses corroborated the above results, showing strong association of Ala499Val (OR = 1.54, CI = 1.21-1.97, p = 0.001) but not that of Lys939Gln (OR = 1.13, CI = 0.95-1.34, p = 0.171) with urinary bladder cancer risk.
|
27246180 |
2016 |
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Numerous studies have investigated the association between three polymorphisms (Lys939Gln, Ala499Val and PAT-/+) of Xeroderma pigmentosum group C (XPC) gene and bladder cancer susceptibility; however, the findings are inconclusive.
|
23918308 |
2014 |
Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this work, we have conducted a case-control study in order to assess the effect of tobacco and three genetic polymorphisms in XPC, ERCC2 and ERCC5 genes (rs2228001, rs13181 and rs17655) in bladder cancer development in Tunisia.
|
21426550 |
2011 |
Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
We examined the associations between bladder cancer and 7 polymorphisms from 5 genes involved in the maintenance of genetic stability (MMR: MLH1-93G>A; BER: XRCC1--77T>C and Arg399Gln; NER:XPC Lys939Gln and PAT +/-; DSBR:ATM G5557A and XRCC7 G6721T) in 302 incident bladder cancer cases and 311 hospital controls.
|
22927776 |
2012 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
|
15886698 |
2005 |
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
A meta-analysis was performed to examine the association between XPC Lys939Gln polymorphism and susceptibility to bladder cancer (BC).
|
23269608 |
2013 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
A meta-analysis was performed to examine the association between XPC Lys939Gln polymorphism and susceptibility to bladder cancer (BC).
|
23269608 |
2013 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our meta-analysis suggested that the XPC Lys939Gln polymorphism contributed to the risk of urinary bladder cancer.
|
23819639 |
2013 |
Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Numerous studies have investigated the association between three polymorphisms (Lys939Gln, Ala499Val and PAT-/+) of Xeroderma pigmentosum group C (XPC) gene and bladder cancer susceptibility; however, the findings are inconclusive.
|
23918308 |
2014 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The distributions of XPC Lys939Gln genotypes differed significantly between the response group (complete + partial responses) and the non-response group (stable + progressive disease; P = 0.022).
|
22166526 |
2010 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interestingly, we found significant correlation between Lys939Gln genotypes and XPC mRNA expression for Asian populations as well.
|
24375193 |
2014 |
Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest an association between the XPC genotypes of the A499V, K939Q and PAT polymorphisms and urinary-bladder cancer.
|
20887739 |
2010 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis based on current evidences suggested that the XPC polymorphisms (Lys939Gln, Val499Arg, and PAT-/+) did not contribute to gastric cancer risk.
|
24886180 |
2014 |
Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analyzed the associations of the genotypes, haplotypes and diplotypes of three XPC polymorphisms, Ala499Val (C-->T), PAT (-/+) and Lys939Gln (A-->C), with the risk of bladder cancer.
|
17052994 |
2007 |
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using logistic regression adjusting for smoking, occupational and family history, neither the heterozygote nor the homozygote variants of these polymorphisms were associated with increased bladder cancer risk (adjusted odds ratio [95% confidence interval] for heterozygote 0.82 [0.63-1.07], 0.82 [0.63-1.08] and 0.83 [0.63-1.08] for PolyAT, IVS11-6 and Lys939Gln, respectively and homozygote variant, 0.98 [0.68-1.42], 0.99 [0.69-1.43] and 1.01 [0.70-1.46]).
|
15886698 |
2005 |
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our meta-analysis suggested that the XPC Lys939Gln polymorphism contributed to the risk of urinary bladder cancer.
|
23819639 |
2013 |
Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated three polymorphisms of the XPC gene (PAT, Ala499Val and Lys939Gln) in 600 subjects with bladder cancer and in 609 healthy controls by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in a Chinese Han population.
|
22505326 |
2012 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The current data suggested that XPC Ala499Val and Lys939Gln polymorphisms may contribute to the identification of patients with increased risk for BC.
|
22519360 |
2012 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
These analyses suggest that XPC Lys(939)Gln, PAT+/- and Ala(499)Val likely contribute to susceptibility to cancers.
|
18771913 |
2008 |